Resources - Slide Sets

MSDHIV.COM - Integrase Inhibition Integrase

RESOURCES— Slide Sets

The following slide sets may be downloaded directly to your desktop.

Congress Presentations

46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)
San Francisco, California, USA, 27-30 September 2006

Potent Antiretroviral Effect of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-Class Resistant Virus

(file size: 130KB) or download zip file (file size: 114KB) The slide set based on protocol 005 has been updated to include new 24-week data recently presented at the 2006 ICAAC meeting in San Francisco. This 15-slide presentation summarizes the properties of MK-0518 as well as the protocol 005 study design, endpoints, patient characteristics, and results.

XVI International AIDS Conference (IAC)
Toronto, Canada, 13-18 August 2006

Potent Antiretroviral Effect of MK-0518, a Novel HIV-1 Integrase Inhibitor, as Part of Combination ART in Treatment-Naïve HIV-1 Infected Patients

(file size: 338KB) or download zip file (file size: 317KB) This slide set, based on protocol 004, has been updated to include new 24-week data. The 13-slide presentation summarizes the properties of integrase inhibitors, and provides background information on MK-0518 before presenting the study design, endpoints, patient characteristics, and results from protocol 004.

13th Conference on Retroviruses and Opportunistic Infections (CROI)
Denver, Colorado, USA, 5-8 February 2006

Potent Antiretroviral Effect of MK-0518, a Novel HIV-1 Integrase Inhibitor, in Patients with Triple-Class Resistant Virus

(file size: 179KB) or download zip file (file size: 112KB) Based on promising preliminary data from our ongoing phase 2 trial program for the novel investigational HIV-1 integrase inhibitor MK-0518, these slides discuss the properties of MK-0518 and detail the study design, interim analysis, and results of protocol 005.

10th European AIDS Conference (EACS)
Dublin, Ireland, 17-20 November 2005

Antiretroviral Effect of MK-0518, a Novel HIV-1 Integrase Inhibitor, in ART-Naive HIV-Infected Patients

(file size: 98KB) or download zip file (file size: 84KB) This slide set is based on promising preliminary data from our ongoing phase 2 trial program for the novel investigational HIV-1 integrase inhibitor MK-0518. The slides summarize the properties of integrase inhibitors, provide background information on MK-0518, and present the study design and results from protocol 004.

HIV Background Information

The following slides are available as support materials in your slide presentations.
	HIV Life Cycle (file size: 1.04MB) or download zip file (file size: 1MB).
	HIV Drug Targets (file size: 214KB) or download zip file (file size: 173KB).

Due to individual countries' requirements, not all uses or indications discussed in this Web site may have received regulatory approval in your country. Before prescribing any of the products mentioned in this Web site, please consult the local prescribing information available from the manufacturer.

†Trademark of Merck & Co., Inc., Whitehouse Station, NJ, USA